Urotensin II (Rat);
[Pyr110]-Prepro-Urotensin II (Rat, 110-123)

4371-v 0.5 mg | 195.00 EUR

Pyr – His – Gly – Thr – Ala – Pro – Glu – Cys – Phe – Trp – Lys – Tyr – Cys – Ile

Synthetic Product (Disulfide bond between Cys⁸– Cys¹³)

This compound has some inherent instability. The purity is guaranteed to be higher than 97% by HPLC

Urotensin II (Rat) is a potent Vasoconstrictor with negative inotropic effects.

Urotensin II (U-II) is a disulfide-linked small peptide initially isolated from fish urophysis. Subsequently, the cDNA sequence encoding the human U-II precursor was determined, and the corresponding mRNA was found to exist predominantly in spinal cord [Proc. Natl. Acad. Sci. USA, 95, 15803 (1998)]. Human U-II, then, was revealed to be an agonist for the orphan receptor GPR14 and exerts a strong vasoconstricting activity in the isolated thoracic aorta of rat [Nature, 401, 282 (1999)]. The potency of vasoconstriction of U-II is an order of magnitude greater than that of endothelin-1, making human U-II the most potent mammalian vasoconstrictor identified so far.

Following the sequence determination of human U-II, the same group reported the corresponding rat peptide cDNA sequence [FEBS Lett., 457, 28 (1999)]. When we look at the deduced peptide sequence of rat prepro-U-II, there are two double basic sites at its C-terminal region, which might be the enzymatic cleavage sites for yielding the mature peptide of rat U-II. We chose the shorter peptide of 14 amino acid residues with pyroglutamic acid modification for Gln¹¹⁰ as the possible candidate for rat U-II and chemically synthesized it. Synthetic [Pyr¹¹⁰ ]-prepro-U-II (110-123) was confirmed to have a vasoconstricting activity as potent as that of human peptide in the isolated thoracic aorta of rat (unpublished result). Therefore, we tentatively named this peptide rat U-II (Urotensin II rat) in our catalog, although the mature form of rat U-II remains to be determined. Recently, Davenport AP & Maguire JJ have predicted the sequence of rat or mouse U-II as prepro-U-II (110-123) [Trends Pharmacol. Sci., 21, 80 (2000)].

References:

1. Y. Coulouarn, S. Jégou, H. Tostivint, H. Vaudry, and I. Lihrmann, FEBS Lett, 457, 28 (1999) (Original)
2. S.M. Gardiner, J.E. March, P.A. Kemp, A.P. Davenport, and T. Bannett, Br. J. Pharmacol, 132, 1625 (2001) (Pharmacol.)

For Laboratory use only! Not for Drug Use!